From: Determinants of treatment in patients with stage IV renal cell carcinoma
All Patientsa | Patients surviving ≥ 6 months | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
No treatment | Surgery only | ST only | Surgery + ST | No treatment | Surgery only | ST only | Surgery + ST | |||
Variable | (n = 486) | (n = 139) | (n = 214) | (n = 110) | P-value | (n = 237) | (n = 146) | (n = 164) | (n = 71) | P-value |
Age at diagnosis | < 0.001 | < 0.001 | ||||||||
Mean (SD) | 78.7 (7.43) | 73.0 (5.39) | 75.3 (5.67) | 72.2 (5.26) | 77.6 (7.39) | 73.5 (5.31) | 75.5 (5.6) | 72.2 (5.19) | ||
Sex | 0.017 | 0.121 | ||||||||
Male | 238 (49.0%) | 70 (50.4%) | 120 (56.1%) | 71 (64.5%) | 59 (49.6%) | 50 (48.5%) | 74 (56.9%) | 60 (63.2%) | ||
Female | 248 (51.0%) | 69 (49.6%) | 94 (43.9%) | 39 (35.5%) | 60 (50.4%) | 53 (51.5%) | 56 (43.1%) | 35 (36.8%) | ||
Race | 0.19 | 0.222 | ||||||||
White | 388 (79.8%) | 119 (85.6%) | 163 (76.2%) | 89 (80.9%) | 95 (79.8%) | 89 (86.4%) | 98 (75.4%) | 76 (80%) | ||
Other | 98 (20.2%) | 20 (14.4%) | 51 (23.8%) | 21 (19.1%) | 24 (20.2%) | 14 (13.6%) | 32 (24.6%) | 19 (20%) | ||
Urban/rural code | 0.424 | 0.119 | ||||||||
Big metro | 232 (47.7%) | 61 (43.9%) | 98 (45.8%) | 62 (56.4%) | 58 (48.7%) | 46 (44.7%) | 53 (40.8%) | 54 (56.8%) | ||
Metro/urban | 184 (37.9%) | 53 (38.1%) | 88 (41.1%) | 35 (31.8%) | n/a | n/a | n/a | n/a | ||
Less urban/rural | 70 (14.4%) | 25 (18.0%) | 28 (13.1%) | 13 (11.8%) | n/a | n/a | n/a | n/a | ||
Other | n/a | n/a | n/a | n/a | 61 (51.3%) | 57 (55.3%) | 77 (59.2%) | 41 (43.2%) | ||
Marital status | < 0.001 | < 0.001 | ||||||||
Unmarried | 304 (62.6%) | 69 (49.6%) | 103 (48.1%) | 33 (30.0%) | 65 (54.6%) | 51 (49.5%) | 67 (51.5%) | 26 (27.4%) | ||
Married | 182 (37.4%) | 70 (50.4%) | 111 (51.9%) | 77 (70.0%) | 54 (45.4%) | 52 (50.5%) | 63 (48.5%) | 69 (72.6%) | ||
Charlson comorbidity index | < 0.001 | 0.056 | ||||||||
Mean (SD) | 1.5 (1.76) | 0.9 (1.31) | 1.1 (1.34) | 1.0 (1.48) | 1.2 (1.58) | 0.9 (1.4) | 1.2 (1.35) | 1.0 (1.4) |